Talazoparib
- TRADE NAME: Talzenna (Pfizer)
- INDICATIONS: indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer.
- CLASS: Poly (ADP-ribose) polymerase (PARP) inhibitor
- HALF-LIFE: 90 hours
FDA APPROVAL DATE: 10/16/2018
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Amiodarone, Carvedilol, Clarithromycin, Itraconazole, Verapamil
PREGNANCY CATEGORY: N/A
can cause embryo-fetal harm
Please login to see the rest of this drug profile
SKIN.
HAIR.
MUCOSAL.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
Page last updated 02/16/2024
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric